Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$30.39
-$0.60(-1.94%)
At close: 4:00 PM EDT
$30.39
-$0.60(-1.94%)
Day’s Range― - ―
52-Week Range$13.50 - $44.60
Previous CloseN/A
Volume558.98K
Average Volume (3M)1.03M
Market Cap
$2.10B
Enterprise Value$1.35K
Total Cash (Recent Filing)$643.13M
Total Debt (Recent Filing)$223.80M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 18, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.62
Shares Outstanding65,176,720
10 Day Avg. Volume846,352
30 Day Avg. Volume1,025,017
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.00Price Target Upside44.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-5.5
Revenue Forecast (FY)$10.22M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressBLA acceptance is a major de-risking milestone that advances obexelimab toward potential commercialization. The 2027 FDA decision date provides a defined path to a first marketed product and could support a durable transition from development to commercial operations.
Clinical PipelineHigh-profile dissemination of Phase 3 data supports the credibility and clinical relevance of obexelimab in autoimmune disease. Additional SLE and ZB021 readouts could broaden the pipeline and create multiple long-term development opportunities.
Improved Equity BaseThe return to positive stockholders’ equity represents a stronger capital base than in earlier periods. Although leverage remains a concern, positive equity provides more financial resilience and may improve the company’s ability to fund ongoing development.
Bears Say
Minimal RevenueThe company has little current revenue to offset a very large cost base, leaving profitability highly dependent on successful clinical development and future commercialization. This weak earnings foundation can persist until a product reaches meaningful market adoption.
Heavy Cash BurnSubstantial and increasing cash consumption raises the likelihood of additional financing before products generate material revenue. Repeated capital needs could dilute shareholders, constrain development choices, or reduce flexibility across the pipeline.
Rising LeverageThe sharp increase in debt adds repayment and financing risk while the company remains loss-making and cash-burning. Higher leverage reduces balance-sheet flexibility and can make future capital raising more difficult or expensive.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $13.50 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $2.10B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 85 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Aug 13, 2026. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.122 by -$0.648.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.22.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 65,176,720 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.122. Following the earnings report the stock price went down -6.679%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (44.78% Upside)
$44.00 (44.78% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 14.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
139.42%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$44.00
▲(44.78% Upside)
Technical Analysis
Ownership Overview
24.38% Insiders
21.98% Mutual Funds
43.18% Other Institutional Investors
2.26% Public Companies and
Individual Investors